Quest Partners LLC Acquires 1,333 Shares of Moderna, Inc. (NASDAQ:MRNA)

Quest Partners LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 12,118.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,344 shares of the company’s stock after purchasing an additional 1,333 shares during the period. Quest Partners LLC’s holdings in Moderna were worth $160,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Moderna by 22.6% during the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock worth $3,372,058,000 after acquiring an additional 6,248,623 shares during the last quarter. Norges Bank bought a new stake in shares of Moderna during the fourth quarter valued at approximately $347,565,000. Wellington Management Group LLP increased its holdings in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in Moderna by 42.9% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after purchasing an additional 463,960 shares during the last quarter. Finally, Matrix Capital Management Company LP bought a new position in Moderna in the 4th quarter worth approximately $45,150,000. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the completion of the sale, the president now owns 1,442,089 shares in the company, valued at $174,665,819.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,158 shares of company stock valued at $11,167,312. Company insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday. Jefferies Financial Group cut Moderna from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $120.00 to $65.00 in a report on Friday. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and reduced their target price for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Finally, Royal Bank of Canada reduced their price objective on shares of Moderna from $90.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $108.53.

Moderna Price Performance

Shares of MRNA opened at $68.28 on Monday. The stock has a 50 day simple moving average of $95.06 and a 200 day simple moving average of $111.89. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The firm has a market capitalization of $26.17 billion, a PE ratio of -4.36 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the company earned ($3.62) earnings per share. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.